Analystreport

Can-Fite BioPharma Ltd. (NYSE: CANF) had its price target raised by analysts at Alliance Global Partners from $8.25 to $12.00.

Can-Fite Biopharma Ltd Sponsored ADR (Israel)  (CANF) 
NASDAQ:AMEX Investor Relations: ir.canfite.com